Cargando…

Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis

Multiple sclerosis is a demyelinating disease affecting the central nervous system. T cells are known to contribute to this immune-mediated condition. Fingolimod modulates sphingosine-1-phosphate receptors, thereby preventing the egress of lymphocytes, especially CCR7-expressing CD8+ and CD4+ T cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friess, Jörg, Hecker, Michael, Roch, Luisa, Koczan, Dirk, Fitzner, Brit, Angerer, Ines Charlotte, Schröder, Ina, Flechtner, Kristin, Thiesen, Hans-Jürgen, Winkelmann, Alexander, Zettl, Uwe Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290459/ https://www.ncbi.nlm.nih.gov/pubmed/28155899 http://dx.doi.org/10.1038/srep42087

Ejemplares similares

MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients
por: Hecker, Michael, et al.
Publicado: (2013)

A genetic variant associated with multiple sclerosis inversely affects the expression of CD58 and microRNA-548ac from the same gene
por: Hecker, Michael, et al.
Publicado: (2019)

Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy
por: Koczan, Dirk, et al.
Publicado: (2018)

Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients
por: Thamilarasan, Madhan, et al.
Publicado: (2013)

Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing
por: Putscher, Elena, et al.
Publicado: (2022)

Implication of genetic variants in primary microRNA processing sites in the risk of multiple sclerosis
por: Hecker, Michael, et al.
Publicado: (2022)

Systematic Review of Studies on Telomere Length in Patients with Multiple Sclerosis
por: Bühring, Jan, et al.
Publicado: (2021)

Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy
por: Hecker, Michael, et al.
Publicado: (2023)

Genetic, Environmental and Lifestyle Determinants of Accelerated Telomere Attrition as Contributors to Risk and Severity of Multiple Sclerosis
por: Hecker, Michael, et al.
Publicado: (2021)

Systemic Effects by Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis
por: Hoeflich, Andreas, et al.
Publicado: (2020)

The Cerebrospinal Fluid in Multiple Sclerosis
por: Deisenhammer, Florian, et al.
Publicado: (2019)

Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes
por: Hecker, Michael, et al.
Publicado: (2021)

Reassessment of Blood Gene Expression Markers for the Prognosis of Relapsing-Remitting Multiple Sclerosis
por: Hecker, Michael, et al.
Publicado: (2011)

Reduced Fragmentation of IGFBP-2 and IGFBP-3 as a Potential Mechanism for Decreased Ratio of IGF-II to IGFBPs in Cerebrospinal Fluid in Response to Repeated Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis
por: Hoeflich, Andreas, et al.
Publicado: (2021)

Principles and Practical Considerations for the Analysis of Disease-Associated Alternative Splicing Events Using the Gateway Cloning-Based Minigene Vectors pDESTsplice and pSpliceExpress
por: Putscher, Elena, et al.
Publicado: (2021)

Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance
por: Hundeshagen, Alexander, et al.
Publicado: (2012)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Polypharmacy in patients with multiple sclerosis: a gender-specific analysis
por: Frahm, Niklas, et al.
Publicado: (2019)

Combining global genome and transcriptome approaches to identify the candidate genes of small-effect quantitative trait loci in collagen-induced arthritis
por: Yu, Xinhua, et al.
Publicado: (2007)

Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study
por: Frahm, Niklas, et al.
Publicado: (2019)

Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry
por: Frahm, Niklas, et al.
Publicado: (2022)

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
por: Bascuñana, Pablo, et al.
Publicado: (2020)

Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors
por: Frahm, Niklas, et al.
Publicado: (2019)

Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort study
por: Winkelmann, Alexander, et al.
Publicado: (2023)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept
por: Koczan, Dirk, et al.
Publicado: (2008)

Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells
por: Derkow, Katja, et al.
Publicado: (2013)

The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients
por: Sáenz-Cuesta, Matías, et al.
Publicado: (2018)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study
por: Blechinger, Stephan, et al.
Publicado: (2021)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

Analysis of microRNA and Gene Expression Profiles in Multiple Sclerosis: Integrating Interaction Data to Uncover Regulatory Mechanisms
por: Freiesleben, Sherry, et al.
Publicado: (2016)

Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK
por: Mazibrada, Gordon, et al.
Publicado: (2018)

Constitutive upregulation of the transforming growth factor-β pathway in rheumatoid arthritis synovial fibroblasts
por: Pohlers, Dirk, et al.
Publicado: (2007)

Robust computational reconstitution – a new method for the comparative analysis of gene expression in tissues and isolated cell fractions
por: Hoffmann, Martin, et al.
Publicado: (2006)

Vaccination in Multiple Sclerosis: Friend or Foe?
por: Zrzavy, Tobias, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oabdv1979m08bq2v3ugkno0f50